Standard Antiparkinsonian Medication

Preclinical

Standard Antiparkinsonian Medication is one of 5 therapeutic programs targeting Parkinson's Disease (PD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Parkinson's Disease (PD)Recruiting

Parkinson's Disease (PD)Preclinical

Recruiting

Competition

Competitive Landscape

8 competitors in Parkinson's Disease (PD)

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

TJ0113

HHangzhou PhecdaMed Co., Ltd.

Phase 3

1 3

AAV2-Haadc

KKrzysztof Bankiewicz

Phase 1

1 4

Buntanetap/posiphen

AAnnovis Bio Inc.

Preclinical

1 5

Standard Antiparkinsonian Medication

RRuijin Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Parkinson's Disease (PD)

NCT07774312

Clinical

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

STN-targeted Temporal Interference Stimulation With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease: A Multicenter, Randomized, Controlled Trial

Recruiting·RRuijin Hospital·Preclinical·NCT07774312·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard Antiparkinsonian Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard Antiparkinsonian Medication. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: RRuijin Hospital

Standard Antiparkinsonian Medication

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Parkinson's Disease (PD)1 trial

References

Drug Info

Quick Facts

Related News